Ph2/3 BCA101 or Placebo or + Pembro for 1st Line PD-L1+ HN SCC
Phase II/III Clinical Trial
A Multicenter Randomized Double-Blind Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BCA101X301)
Participating Locations